287730-14-7

Basic information

• Product Name: 5,6-dichloro-1H-Benzimidazole-2-carboxylic acid
• Synonyms: 5,6-dichloro-1H-Benzimidazole-2-carboxylic acid
• CAS NO: 287730-14-7
• Molecular Formula: C₈H₄Cl₂N₂O₂
• Molecular Weight: 231.03556
• Mol File: 287730-14-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5,6-dichloro-1H-Benzimidazole-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5,6-dichloro-1H-Benzimidazole-2-carboxylic acid(287730-14-7)
• EPA Substance Registry System: 5,6-dichloro-1H-Benzimidazole-2-carboxylic acid(287730-14-7)

Safety Data

• Hazardous Substances Data: 287730-14-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5,6-dichloro-1H-Benzimidazole-2-carboxylic acid is used as an antifungal agent for its ability to inhibit the growth of certain fungi, making it a potential candidate for treating fungal infections.
5,6-dichloro-1H-Benzimidazole-2-carboxylic acid is also used as an antibacterial agent, given its capacity to suppress the growth of specific bacteria, which could be beneficial in combating bacterial infections.
Used in Oncology Research:
In the field of oncology, 5,6-dichloro-1H-Benzimidazole-2-carboxylic acid is used as a potential anti-cancer agent. Research has shown that it can induce cell death in cancer cells, offering a promising avenue for the development of new cancer therapies.
Used in Biotechnology:
5,6-dichloro-1H-Benzimidazole-2-carboxylic acid is utilized in biotechnology for its potential to contribute to the development of novel treatments and diagnostic tools, given its diverse biological activities and chemical properties.

Upstream product

• 3584-64-3 5,6-dichloro-2-trichloromethyl-1H-benzoimidazole 
• 5348-42-5 4,5-Dichloro-1,2-phenylenediamine 
• 6478-80-4 5,6-dichloro-2-hydroxymethyl-1H-benzimidazole 

Downstream Products

• 1352002-37-9 5,6-dichloro-2-[(4-phenylpiperazin-1-yl)carbonyl]-1H-benzimidazole 
• 1352002-38-0 5,6-dichloro-2-{[4-(2-methoxyphenyl)piperazin-1-yl]carbonyl}-1H-benzimidazole 
• 1352002-40-4 5,6-dichloro-2-{[4-(4-nitrophenyl)piperazin-1-yl]carbonyl}-1H-benzimidazole 
• 1352002-39-1 5,6-dichloro-2-{[4-(4-fluorophenyl)piperazin-1-yl]carbonyl}-1H-benzimidazole 

Relevant articles and documents

Disrupting the Conserved Salt Bridge in the Trimerization of Influenza A Nucleoprotein

Antiviral drug resistance in influenza infections has been a major threat to public health. To develop a broad-spectrum inhibitor of influenza to combat the problem of drug resistance, we previously identified the highly conserved E339?R416 salt bridge of the nucleoprotein trimer as a target and compound 1 as an inhibitor disrupting the salt bridge with an EC50 = 2.7 μM against influenza A (A/WSN/1933). We have further modified this compound via a structure-based approach and performed antiviral activity screening to identify compounds 29 and 30 with EC50 values of 110 and 120 nM, respectively, and without measurable host cell cytotoxicity. Compared to the clinically used neuraminidase inhibitors, these two compounds showed better activity profiles against drug-resistant influenza A strains, as well as influenza B, and improved survival of influenza-infected mice.

Molecular properties prediction and synthesis of new benzimidazole H4-receptor antagonists as anti-inflammatory agents

This investigation deals with the design and calculation of molecular properties, drug likeness, lipophilicity and solubility parameters of substituted benzimidazolyl carbonyl piperazines/piperidines using Mol inspiration, Mol soft, Software's and ALOPGPS 2.1 program. Toxicity parameters were calculated using Osiris Software. All compounds are non toxic; fulfill the solubility requirements and passing oral bioavailability criteria. The compounds were synthesized and characterized by IR, 1H NMR and Mass spectral analysis. Most of the compounds exhibited significant antiinflammatory activity.

Synthesis of some new 1H-benzimidazole-2-carboxamido derivatives and their antimicrobial activitiy

5,6-Dichloro-2-hydroxymethyl-1H-benzimidazole (1) was prepared by the cyclization of 4,5-dichloro-o-phenylenediamine with glycolic acid, then, alcohol group of 1 was converted to carboxylic acid (2). The final products 5,6-dichloro-1H-benzimidazole-2-carb

BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS

The present invention relates to benzimidazole carboxamides of formula (I), the use of the compounds of formula (I) as inhibitors of as inhibitors of one or more kinases, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient. Accordingly, the compound of Formula (I) or a pharmaceutically acceptable salt thereof is administered for the treatment of diseases mediated by one or more kinase phathways, preferably by the raf kinase pathway, especially cancers.

Benzimidazoles as NMDA glycine-site antagonists: Study on the structural requirements in 2-position of the ligand

A series of different substituted benzimidazole derivatives has been synthesized and evaluated for the ability to displace [3H]MDL-105,519 to rat cortical membranes. Two benzimidazole-2-carboxylic acids 9 b and 9 c, in this substitution pattern not yet described as glycine antagonists, showed IC50 values of 0.89 μM (9 b) and 38.0 μM (9 c). Replacement of the carboxylate function in 2-position by a sulfonic acid moiety appreciably increased solubility, but decreased the affinity giving evidence for the strong need of the carboxylate group within the ligand. Further structure-activity studies using benzimidazol-2-one derivatives with an acetic acid moiety adjacent to a ring nitrogen revealed new insights into the importance of amide functionalities within the heterocycle for the affinity of antagonist glycine-site ligands.